drugset / Trial / NCT02501928

Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.

NCT02501928

Phase 3 Completed 12 enrolled Pfizer
Non-randomizedOpen-labelTreatment

Summary

The purpose of this study is to investigate the safety and tolerability of fesoterodine following once daily long-term treatment in Japanese pediatric neurogenic detrusor overactivity (NDO) subjects.

Timeline

Start
2015-06-05
Primary completion
2020-04-01
Completion
2020-04-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fesoterodine Other / unclassified 2 mg
Subject Fesoterodine Other / unclassified 4 mg
Subject Fesoterodine Other / unclassified 8 mg